argenx SE ADR ARGX 深 沪
已收盘 12-19 16:00:00 美东时间
854.92
+7.870
+0.93%
华盛通- 最 高934.6199
- 今 开851.48
- 成交量 32.07万股
- 最 低 827.52
- 昨 收 847.05
- 总市值 463.70亿
- 52周最高 934.6199
- 市盈率 静 --
- 换手率 0.59%
- 52周最低 510.055
- 委 比 31.09%
- 总股本 5423.86万
- 历史最高 934.6199
- 量 比 0.91
- 振 幅 12.64%
- 历史最低 1.10
- 每 手 1
- 风险率 111.42%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Baird Downgrades argenx to Neutral, Lowers Price Target to $858
Baird analyst Colleen Kusy downgrades argenx (NASDAQ:ARGX) from Outperform to Neutral and lowers the price target from $924 to $858.
12-18 19:01
Argenx, Navan And 3 Stocks To Watch Heading Into Monday
Stock futures up, focus on HYFT, ARGX, NAVN, AXR, CSBR as they report earnings. Top 2 energy stocks to watch for potential plunge this month.
12-15 15:42
Wolfe Research Downgrades argenx to Peer Perform
Wolfe Research analyst Andy Chen downgrades argenx (NASDAQ:ARGX) from Outperform to Peer Perform.
11-24 19:00
argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy
VYVGART® SC, a groundbreaking IgG Fc-antibody fragment targeting FcRn, has been approved in Europe for CIDP treatment. Based on the ADHERE trial, this novel therapy offers significant clinical improvement and reduced relapse risk, marking a major advancement for CIDP patients after over 30 years of limited treatment options.
06-20 17:00
argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren’s Disease
argenx announces positive Phase 2 results for efgartigimod in myositis and Sjogren’s disease, achieving significant improvements in muscle strength, systemic disease activity, and autoantibody reduction. The drug received FDA Fast Track designation and is advancing in Phase 3 studies, targeting IgG autoantibodies via FcRn inhibition.
06-10 22:01
港股创新药涨疯了，常山直接2个20cm！东吴：2025是3年行情元年
炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ （来源：金石杂谈） 转自：金石杂谈 6月9日，创新药继续狂飙，港股创新药，尤其B类医药股，纷纷10cm以上大肉，中国抗体、欧康维视生物、金斯瑞生物、四环医药等纷纷大涨。 尤其下面这张图，含金量会不断上升，百济、恒瑞、信达、翰森等都是创新药龙头。 不知不觉，在港股创新药暴涨之际，A股创新药概念同样暴涨，星昊医药暴涨26%，海辰药业、常山制药直接20cm涨停。 常山药业连续2日20cm，今年以来暴涨160%，公司股价暴涨背后，到底涨什么？有人说是减肥药，也有人说是创新药；而6月6日的龙虎榜显示，前五席位有三个是机构，可见...
06-10 00:16
港股创新药涨疯了，常山直接2个20cm！东吴：2025是3年行情元年
6月9日，创新药继续狂飙，港股创新药，尤其B类医药股，纷纷10cm以上大肉，中国抗体、欧康维视生物、金斯瑞生物、四环医药等纷纷大涨。 尤其下面这张图，含...
06-09 16:52
医药主题产品霸榜！对话知名基金经理万民远：为什么他说当下创新药“大部分都是纯炒”
2025年创新药板块迎来爆发式行情。 A股创新药指数年内大涨超20%，港股创新药指数涨幅接近50%，百济神州、康方生物等龙头股表现抢眼。汇添富国证港股通创新药...
06-05 22:13
argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference
argenx announced that Karl Gubitz, its Chief Financial Officer, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025, in Miami, FL.
06-03 05:00
argenx Announces Results of Annual General Meeting of Shareholders
argenx SE held its Annual General Meeting on May 27, 2025, with 91.1% of shares represented. All agenda items passed except for item 5, which received 73.0% support. Key resolutions included approval of the 2024 remuneration report, annual report, and reappointment of Anthony Rosenberg to the Board. Share issuance authorization and updates on argenx's immunology work were also approved.
05-28 20:01
